Analyzing DNA directly on our novel microchip provides rapid and accurate results from a user-friendly system. LiDia can operate in a variety of hospital environments close to the point of need, with flexible levels of throughput to match a wide range of clinical demands.

LiDia launches with a groundbreaking rapid direct-from-specimen test for bloodstream infections that lead to sepsis, followed by a pipeline of tests that provide fast results for serious medical applications such as cancer monitoring.

threat of AMR. In September 2016, DNAe was awarded up to $51.9M contract by the Biomedical Advanced Research and Development Authority, a division of the Office of the Assistant Secretary for Preparedness and Response in the US Health and Human Services to develop a semiconductor DNA sequencing platform for rapid diagnosis of antimicrobial resistant infections and influenza.

We’re creating something radically different products that change the game for early diagnosis and monitoring of potentially fatal diseases. The work we do at DNAe helps save lives, this is a powerful motivator and a glorious reason to get involved.